

Age-Related Vision Dysfunction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/A4D011FE52A4EN.html>

Date: May 2024

Pages: 139

Price: US\$ 6,499.00 (Single User License)

ID: A4D011FE52A4EN

Abstracts

The 7 major age-related vision dysfunction markets reached a value of US\$ 63.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 85.1 Million by 2034, exhibiting a growth rate (CAGR) of 2.76% during 2024-2034.

The age-related vision dysfunction market has been comprehensively analyzed in IMARC's new report titled "Age-Related Vision Dysfunction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Age-related vision dysfunction refers to a range of visual impairments that commonly manifest as people grow older. It is a natural part of the aging process and can impact various aspects of visual function. The common symptoms often include diminished visual acuity, decreased ability to focus on close objects (presbyopia), reduced contrast sensitivity, and increased susceptibility to glare and night vision difficulties. These issues can significantly affect daily activities, such as reading, driving, and recognizing faces. Diagnosis of the ailment involves comprehensive eye examinations conducted by qualified optometrists or ophthalmologists. These investigations assess factors like visual acuity, refraction, and the health of the eye's internal structures, including the lens and retina. Tonometry may also be performed to measure intraocular pressure, helping to detect glaucoma, a condition often associated with aging eyes. Additionally, specialized tests might be conducted to evaluate contrast sensitivity and visual field, which can provide a thorough understanding of the patient's visual capabilities.

The expanding geriatric population, who are susceptible to retinal detachment, in which the gel-like vitreous inside the eye may shrink and pull away from the retina, leading to floaters and flashes, is primarily driving the age-related vision dysfunction market. In addition to this, the inflating utilization of potent medications, such as antioxidants, anti-

VEGF injections, anti-inflammatory agents, etc., to control disease progression and mitigate symptoms is also creating a positive outlook for the market. Moreover, the widespread adoption of corrective surgical interventions, including cataract removal and lens replacement surgeries, is further bolstering the market growth. Apart from this, the rising usage of rehabilitative visual therapies, as they aid in maximizing the remaining vision, enhancing visual adaptation, and facilitating better daily living skills, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, which emphasizes introducing or modifying genetic material in cells to rectify or replace the deteriorating genes linked to vision loss, is also augmenting the market growth. Furthermore, the escalating demand for innovative technologies, such as retinal implants and artificial vision systems, since they hold the potential to restore partial vision in patients with severe visual impairments, is expected to drive the age-related vision dysfunction market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the age-related vision dysfunction market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for age-related vision dysfunction and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the age-related vision dysfunction market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France

United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the age-related vision dysfunction market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the age-related vision dysfunction market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current age-related vision dysfunction marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the age-related vision dysfunction market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the age-related vision dysfunction market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the age-related vision dysfunction market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of age-related vision dysfunction across the seven major markets?

What is the number of prevalent cases (2018-2034) of age-related vision dysfunction by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of age-related vision dysfunction by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with age-related vision dysfunction across the seven major markets?

What is the size of the age-related vision dysfunction patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of age-related vision dysfunction?

What will be the growth rate of patients across the seven major markets?

Age-Related Vision Dysfunction: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for age-related vision dysfunction drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the age-related vision dysfunction market?

What are the key regulatory events related to the age-related vision dysfunction market?

What is the structure of clinical trial landscape by status related to the age-related vision dysfunction market?

What is the structure of clinical trial landscape by phase related to the age-related vision dysfunction market?

What is the structure of clinical trial landscape by route of administration related to the age-related vision dysfunction market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 AGE-RELATED VISION DYSFUNCTION - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 AGE-RELATED VISION DYSFUNCTION - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 AGE-RELATED VISION DYSFUNCTION - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (?2018-2034?)
- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 AGE-RELATED VISION DYSFUNCTION - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 AGE-RELATED VISION DYSFUNCTION - UNMET NEEDS

10 AGE-RELATED VISION DYSFUNCTION - KEY ENDPOINTS OF TREATMENT

11 AGE-RELATED VISION DYSFUNCTION - MARKETED PRODUCTS

- 11.1 List of Age-Related Vision Dysfunction Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Vuity (Pilocarpine Hydrochloride Ophthalmic Solution) - Allergan
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results
 - 11.1.1.5 Sales Across Major Markets
 - 11.1.2 Lucentis (Ranibizumab Injection) - Genentech/Novartis Ophthalmics

- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Vabysmo (Faricimab-Svoa) - Genentech
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Macugen (Pegaptanib Sodium Injection) - Pfizer
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Beovu (Brolucizumab) - Novartis
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 AGE-RELATED VISION DYSFUNCTION - PIPELINE DRUGS

- 12.1 List of Age-Related Vision Dysfunction Pipeline Drugs Across the Top 7 Markets
 - 12.1.1 Drug Name – Company Name
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. AGE-RELATED VISION DYSFUNCTION - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. AGE-RELATED VISION DYSFUNCTION – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 AGE-RELATED VISION DYSFUNCTION - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Age-Related Vision Dysfunction - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Age-Related Vision Dysfunction - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Age-Related Vision Dysfunction - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Age-Related Vision Dysfunction - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Age-Related Vision Dysfunction - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Age-Related Vision Dysfunction - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
- 15.5 Market Scenario - France
 - 15.5.1 Age-Related Vision Dysfunction - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
 - 15.5.2 Age-Related Vision Dysfunction - Market Size by Therapies

- 15.5.2.1 Market Size by Therapies (2018-2023)
- 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Age-Related Vision Dysfunction - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Age-Related Vision Dysfunction - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Age-Related Vision Dysfunction - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Age-Related Vision Dysfunction - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Age-Related Vision Dysfunction - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Age-Related Vision Dysfunction - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Age-Related Vision Dysfunction - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Age-Related Vision Dysfunction - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Age-Related Vision Dysfunction - Access and Reimbursement Overview

16 AGE-RELATED VISION DYSFUNCTION - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 AGE-RELATED VISION DYSFUNCTION MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 AGE-RELATED VISION DYSFUNCTION MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Age-Related Vision Dysfunction Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/A4D011FE52A4EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A4D011FE52A4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

